Liu Yulan, Lei Hongbo, Zhang Jixiang, Wang Jun, Li Kui, Dong Weiguo
Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, China.
Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
PLoS One. 2015 Aug 12;10(8):e0135318. doi: 10.1371/journal.pone.0135318. eCollection 2015.
Several studies have been conducted to examine the associations between osteopontin (OPN) promoter gene SPP1 polymorphisms with human cancers in Chinese population, but the results remain inconsistent. The aim of this meta-analysis is to clarify the associations between SPP1 polymorphisms and cancer susceptibility.
All eligible case-control studies published up to March 2015 were identified by searching PubMed, Web of Science, Embase, and Cochrane Library without language restrictions. Pooled odds ratio (OR) and 95% confidence interval (95% CI) were calculated using fixed- or random-effect model.
A total of 11 case-control studies were included; of those, there were eleven studies (3130 cases and 3828 controls) for -443T>C polymorphism, ten studies (3019 cases and 3615 controls) for -156G>GG polymorphism, eight studies (2258 cases and 2846 controls) for -66T>G polymorphism. Overall, no evidence indicated that the -443 T>C polymorphism was associated with cancer risk (OR = 0.93, 95%CI 0.62-1.38 for dominant model, OR = 1.06, 95%CI 0.73-1.55 for recessive model, OR = 0.88, 95%CI 0.62-1.26 for CT vs TT model, OR = 1.03, 95%CI 0.61-1.73 for CC vs TT model). While, a significantly increase risk was found for -156 G>GG polymorphism (OR = 1.22, 95%CI 1.10-1.35 for dominant model, OR = 1.25, 95%CI 1.10-1.41 for recessive model, OR = 1.18, 95%CI 1.06-1.32 for GGG vs GG model, OR = 1.35, 95%CI 1.09-1.68 for GGGG vs GG model). For -66T>G polymorphism, we found a decrease risk of cancer (OR = 0.84, 95% CI 0.71-0.98 for dominant model), but this result changed (OR = 0.93, 95% CI 0.77-1.12 for dominant model) when we excluded a study.
This meta-analysis suggests that in Chinese population the -156G>GG polymorphism of SPP1 might be a risk factor for human cancers, while -443T>C mutation is not associated with cancer risk. For -66T>G polymorphism, it may be a protective factor for human cancers.
已有多项研究探讨骨桥蛋白(OPN)启动子基因SPP1多态性与中国人群人类癌症之间的关联,但结果仍不一致。本荟萃分析的目的是阐明SPP1多态性与癌症易感性之间的关联。
通过检索PubMed、Web of Science、Embase和Cochrane图书馆,确定截至2015年3月发表的所有符合条件的病例对照研究,无语言限制。使用固定效应或随机效应模型计算合并比值比(OR)和95%置信区间(95%CI)。
共纳入11项病例对照研究;其中,-443T>C多态性研究11项(3130例病例和3828例对照),-156G>GG多态性研究10项(3019例病例和3615例对照),-66T>G多态性研究8项(2258例病例和2846例对照)。总体而言,没有证据表明-443 T>C多态性与癌症风险相关(显性模型下OR = 0.93,95%CI 0.62 - 1.38;隐性模型下OR = 1.06,95%CI 0.73 - 1.55;CT与TT模型下OR = 0.88,95%CI 0.62 - 1.26;CC与TT模型下OR = 1.03,95%CI 0.61 - 1.73)。然而,发现-156 G>GG多态性的风险显著增加(显性模型下OR = 1.22,95%CI 1.10 - 1.35;隐性模型下OR = 1.25,95%CI 1.10 - 1.41;GGG与GG模型下OR = 1.18,95%CI 1.06 - 1.32;GGGG与GG模型下OR = 1.35,95%CI 1.09 - 1.68)。对于-66T>G多态性,我们发现癌症风险降低(显性模型下OR = 0.84,95% CI 0.71 - 0.98),但排除一项研究后该结果发生了变化(显性模型下OR = 0.93,95% CI 0.77 - 1.12)。
本荟萃分析表明,在中国人群中,SPP1的-156G>GG多态性可能是人类癌症的一个危险因素,而-443T>C突变与癌症风险无关。对于-66T>G多态性,它可能是人类癌症的一个保护因素。